Immunotherapy is currently at the stage of drug development (recently reviewed in [68,69,70]), and, as of today, eight humanized tau antibodies and two tau vaccines are under clinical trial for AD or frontotemporal dementia [71] (www.alzforum.org). The gene discussed is MAPT; the disease is Alzheimer disease.